THC, CBD and Chronic Pain: What the Evidence Actually Supports
Cannabis products are widely used for chronic pain, but the evidence does not support a single “best strain”—or a simple choice between THC and CBD. Research suggests that some non-inhaled cannabis-based medicines may provide modest, short-term pain relief for some adults, particularly when they contain THC. The benefits must be weighed against side effects, uncertain long-term safety and the limited evidence for many products sold commercially.
A 2021 systematic review and meta-analysis published in The BMJ examined 32 randomized trials involving 5,174 adults with chronic pain. Most studies lasted between one and 5.5 months and evaluated oral or topical products rather than smoked or vaporized cannabis. Compared with placebo, non-inhaled cannabis medicines produced small improvements in pain, physical function and sleep. The review did not establish that cannabis eliminates pain or works better than standard treatments.
How THC and CBD differ
THC, or tetrahydrocannabinol, is the cannabinoid primarily responsible for cannabis’s intoxicating effects. It acts directly on cannabinoid receptors involved in pain processing and can produce analgesia, sedation and relaxation. THC-containing medicines were the most common products studied in clinical trials, either alone or combined with CBD.
THC can also cause dizziness, drowsiness, impaired coordination, difficulty concentrating, anxiety or paranoia. These effects may be especially concerning for older adults, people at risk of falls and anyone who must drive or operate machinery. The amount of THC that provides tolerable pain relief varies considerably from person to person.
CBD, or cannabidiol, does not usually cause the “high” associated with THC. It influences several biological signaling systems, including pathways involved in inflammation, mood and pain, but its effects should not be described as identical to THC’s. Evidence for CBD used by itself to treat chronic pain remains limited. In the BMJ review, most of the clinical evidence involved THC-containing products, while relatively few trials evaluated CBD alone.
CBD is not risk-free. Possible adverse effects include diarrhea, sleepiness, changes in appetite and changes in alertness or mood. The U.S. Food and Drug Administration warns that CBD can interact with other medicines and may cause liver injury. Anyone taking prescription drugs—particularly medicines processed by the liver—should discuss CBD with a healthcare professional before using it.
Why “strain” is not a reliable medical answer
Labels such as indica, sativa and hybrid do not reliably predict a product’s medical effects. Products with the same strain name can differ in their THC, CBD, terpene and contaminant content, and unregulated products may not contain exactly what their labels claim. For medical decision-making, the cannabinoid profile, dose, delivery method and product quality matter more than a strain name.
There is also no strong evidence that a particular cannabis strain is optimal for chronic pain. The available trials generally studied standardized medicines rather than the wide range of retail flower and extract products available in dispensaries. Results from oral or sublingual medicines therefore may not apply to smoking or vaping.
What patients should consider
If a clinician and patient decide to try a cannabis-based medicine, a product with a known cannabinoid concentration and a clearly documented source is preferable. Because THC-related side effects are dose-dependent, clinicians commonly take a cautious approach, beginning with a low dose and increasing slowly when appropriate. Oral products can take longer to produce effects and may last longer than expected, which increases the risk of taking too much.
Cannabis should not be viewed as a proven replacement for comprehensive pain care. Treatment decisions should account for the cause of the pain, other medications, mental health history, pregnancy or breastfeeding, fall risk and any history of substance-use disorder. Cannabis should not be combined with alcohol or other sedating drugs without medical advice, and people using an intoxicating product should not drive.
The International Association for the Study of Pain does not endorse the general use of cannabinoids for pain because it considers the evidence on effectiveness and safety insufficient for a broad recommendation. Its position reflects important gaps in research, including which patients benefit, the best doses and delivery methods, and the consequences of long-term use.
In practical terms, THC-containing medicines may offer modest short-term relief for some people with chronic pain, while CBD alone has not been established as a consistently effective pain treatment. There is no scientifically validated “best cannabis strain.” Anyone considering cannabis for chronic pain should review the potential benefits and risks with a qualified healthcare professional rather than relying on strain names or product marketing.
